About: Samuel D. Waksal

An Entity of Type: animal, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released.

Property Value
dbo:abstract
  • Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released. (en)
dbo:activeYearsStartYear
  • 1979-01-01 (xsd:gYear)
dbo:birthDate
  • 1947-09-08 (xsd:date)
dbo:birthYear
  • 1947-01-01 (xsd:gYear)
dbo:board
dbo:knownFor
dbo:occupation
dbo:wikiPageExternalLink
dbo:wikiPageID
  • 70146 (xsd:integer)
dbo:wikiPageLength
  • 17620 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID
  • 1113474437 (xsd:integer)
dbo:wikiPageWikiLink
dbp:almaMater
  • Ohio State University (en)
dbp:birthDate
  • 1947-09-08 (xsd:date)
dbp:birthPlace
  • Paris, France (en)
dbp:boards
  • Cadus Corporation, Antigenics Inc., Test University, Rockefeller University (en)
dbp:citizenship
  • United States (en)
dbp:criminalCharge
dbp:criminalPenalty
  • 2.287926E8
dbp:criminalStatus
  • released (en)
dbp:education
  • PhD (en)
dbp:knownFor
  • Founder of ImClone Systems and Kadmon Pharmaceuticals (en)
dbp:name
  • Samuel D. Waksal (en)
dbp:nationality
  • American (en)
dbp:occupation
  • Scientist, biotechnology executive (en)
dbp:wikiPageUsesTemplate
dbp:yearsActive
  • 1979 (xsd:integer)
dcterms:subject
schema:sameAs
rdf:type
rdfs:comment
  • Samuel D. Waksal (born September 8, 1947) is the founder and former CEO of the biopharmaceutical company ImClone Systems. He is also the founder of Kadmon Pharmaceuticals, which was financed with private capital and commenced operations in New York City in 2010. At ImClone, Waksal led the company to develop the cancer drug Erbitux (cetuximab). During the course of its review process with the Food and Drug Administration (FDA) Waksal became involved in an insider trading scandal revolving around improper communications with personal friends and family members. He was convicted of several securities violations, served time in federal prison, and was released. (en)
rdfs:label
  • Samuel D. Waksal (en)
owl:sameAs
prov:wasDerivedFrom
foaf:isPrimaryTopicOf
foaf:name
  • Samuel D. Waksal (en)
is dbo:foundedBy of
is dbo:wikiPageRedirects of
is dbo:wikiPageWikiLink of
is dbp:founder of
is foaf:primaryTopic of
Powered by OpenLink Virtuoso    This material is Open Knowledge     W3C Semantic Web Technology     This material is Open Knowledge    Valid XHTML + RDFa
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License